Sara A. Hurvitz, MD, on HER2-Positive Metastatic Breast Cancer: T-DXd vs T-DM1
2021 San Antonio Breast Cancer Symposium
Sara A. Hurvitz, MD, of the University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses phase III findings from the DESTINY-Breast03 trial, which compared ado-trastuzumab deruxtecan (T-DXd) with standard-of-care trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. T-DXd showed superior progression-free survival across subgroups of patients previously treated with trastuzumab and a taxane, including those with brain metastases (Abstract GS3-01).
The ASCO Post Staff
Kevin Kalinsky, MD, of the Winship Cancer Institute at Emory University, discusses updated phase III results from the SWOG S1007 (RxPONDER) study of women with one to three positive lymph nodes, and hormone receptor–positive, HER2-negative breast cancer. The data showed that postmenopausal women with recurrence scores (RS) from 0 to 25 continue not to benefit from adjuvant chemotherapy, whereas premenopausal women with a RS from 0 to 25 did benefit from the addition of chemotherapy to endocrine therapy (Abstract GS2-07).
The ASCO Post Staff
Charles Coombes, MD, PhD, of Imperial College, London, discusses study results on samuraciclib, a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor–positive HER2-negative breast cancer. The combination of agents has demonstrated evidence of anti-tumor activity for patients who have progressed on their prior CDK4/6 inhibitor treatment (Abstract GS3-10).
The ASCO Post Staff
Peter Schmid, MD, PhD, of Barts Cancer Institute, discusses phase III findings from KEYNOTE-522, in which researchers found a generally consistent event-free survival benefit among patients with early-stage high-risk triple-negative breast cancer who were treated with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab (Abstract GS1-01).
The ASCO Post Staff
François-Clément Bidard, MD, PhD, of the Institut Curie, discusses phase III findings of the PADA-1 study, which showed that optimizing endocrine therapy after detecting the ESR1 mutation in patients with hormone receptor–positive, HER2-negative metastatic breast cancer may double their median progression-free survival (Abstract GS3-05).
The ASCO Post Staff
Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber Brigham and Women’s Cancer Center, discusses the progress made in recent years treating patients with triple-negative breast cancer (TNBC), including approval of the immunotherapy agents pembrolizumab and sacituzumab govitecan-hziy, a new standard of care in the preoperative setting for early-stage disease, as well as a better understanding of the biology of TNBC and its heterogeneity.
